{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} Terlipressin for Hepatorenal Syndrome: The Practical Choice for Clinicians

Activity Steps


Method of Participation in the Learning Process/Evaluation Method

Successful completion of this activity includes reading the entire article and successfully completing the post-quiz and an evaluation form.

Getting the Most out of the Activity

As you prepare to participate in this activity, please reflect on your practice and your patients and identify clinical challenges you hope to have addressed.

While participating in the training, identify ways you can use newly acquired knowledge, strategies, and skills to enhance patient outcomes and your own professional development.

Learning Objectives

After completing this continuing education activity you will be able to:

  1. Describe the criteria for Hepatorenal Syndrome, the primary indication for terlipressin.
  2. Explain the role of terlipressin in the treatment of Hepatorenal Syndrome and its limitations.
  3. Compare terlipressin to other treatment options for hepatorenal syndrome.
Price: $30.00


  • ACCME 1.0 CME

Lippincott Continuing Medical Education Institute, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Lippincott Continuing Medical Education Institute, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Professions: Physician
Test Code: CLD1123C
Published: November 2023
Expires: 10/31/2025
Required Passing Score: 3/4 (75%)
Authors: Nabeel Wahid, Andres Duarte-Rojo and Justin R. Boike
Categories: Hepatology
Specialties: Hepatology